Breakout Candidate; DVAX
- Posted by ZorTrades
- on October 11th, 2012
Clear catalyst for DVAX; FDA advisory panel for its main drug-HEPLISAV on November 14…Trade in anticipation.
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment. I or my affiliates may hold positions or other interests in securities mentioned in the Blog, please see my Disclaimer page for my full disclaimer.
blog comments powered by Disqus
-
Frank Zorrilla is the founder and chief investment officer of Zor Capital LLC.He began his Wall Street career 10 days after his 20th birthday when he became a Series 7 licensed stock broker. More »
-
-
Recent Posts
-
Archives
-
